ImetelChat

Here is some interesting reading while we spend time at home. Geron is expanding R and D and not in a small way. They must think the money will come from somewhere e.g. a partner or AA. Love the optimism. Here is a recent article, note the conclusion section. Bill maybe give us your take? https://ww...

Fellow board members (for those who are left), it is very trying time not just for investors but most importantly patients and their families. The COVID-19 pandemic has affected us all and I wish those who are ill a speedy recovery and send condolences for those who have died. Even Scarlett addresse...

karagozoglu, I have always appreciated your contribution to this board. Since the stock is at its lowest point in history, every stock owner who has held, shares your disappointment and have experienced losses (by definition). Best Wishes for future success and if you haven't sold I hope you (and th...

Yes, its a special bird that snatches your money and flies away.

Also I see you have run into the irritating spell correction which always changes Geron into a bird. bp

musketeer, Well, either the jobs were filled or Scarlett decided not to hire them after all. The latter very unlikely since stock options were issued. It appears the Scarlett continues to build a team that has the intention of manufacturing and marketing Imetelstat. The question is when. bp

https://ir.geron.com/investors/press-re ... fault.aspx

Where"s the part about discussing "recent events"?

The MF study is now listed as completed and the MDS study has had more sites added for a total of 58 sites recruiting. Since many of the enrolling sites are in South Korea, Italy and Israel it is reasonable to expect that enrollments in these centers will be delayed due to Covid-19. bp

But Geron kept Sergei's patents.

Bill, thank you for your contributions as always. One thing about the ongoing studies you cite and there are many listed, have you seen any that suggest actual disease modification? Even the last Abbvie Venetoclax study update released yesterday in AML did not statistically prolong life even though ...

rccola335, the Italian study on MOS certainly raised an eyebrow, but the FDA in looking at RWD would probably take a magnifying glass to the actual statistical analysis such as looking carefully at age/disease matched controls to be sure the comparisons are valid between the treatment group and the ...

EOM

Commsman, the evil and sadness of cancer has affected us all. Thank you for sharing this touching family story. bp

Ryan, I think you were the one who said Geron was screening on the basis of molecular signature and I took issue since there was no mention on the clinical trials site. Looks like you will tun out to be right for future use!! I hope so. Regards, bp

Worth a read in light of the WIPO post:

https://www.nature.com/articles/leu2013 ... rigin=ppub

For those of you who obsessively check Geron's home page (I do, but mostly out a a sense of obligation to this board) its pretty clear that the careers section hasn't been updated despite the high probability that the positions have been filled several weeks ago and the options that attach issued. S...

https://s24.q4cdn.com/668523011/files/doc_presentations/2020/Geron-Corporate-Presentation-JPM-Jan-2020-01.13.2020-FINAL.pdf A few observation about the new presentation. 1. Emphasis on new class and IP protection to 2033 (they will need it at this rate). 2. New PIII MDS proposals to FDA--this does n...

STA, I agree completely with your thoughts. A combo study would probably be the slowest path, possibly requiring a PII first. I have been intrigued by this statement in the last PR: " (i) whether regulatory authorities permit the further development of imetelstat for relapsed/refractory MF before Ge...